Eighteen‐Months Safety and Efficacy Following Intraperitoneal Treatment With <sup>224</sup>Radium‐Labeled Microparticles After CRS‐HIPEC in Patients With Peritoneal Metastasis From Colorectal Cancer
Radspherin was well tolerated. At 18 months, median disease-free survival has not been reached, and none of the patients receiving the recommended dose (7 MBq) had peritoneal recurrences. The results are encouraging and warrant further clinical evaluation.
Authors
- Roy H. Larsen (ORCID: https://orcid.org/0000-0002-9295-7656)
- Olaf Sørensen (ORCID: https://orcid.org/0000-0002-3619-1203)
- Trine Jensen Gjertsen
- Nadja Lundstrøm
- Øyvind S. Bruland (ORCID: https://orcid.org/0000-0003-1631-3733)
- W. Graf (ORCID: https://orcid.org/0000-0003-0460-4605)
- Milan Spasojevic
- Stein Gunnar Larsen (ORCID: https://orcid.org/0000-0002-9831-1995)
- Anne-Kirsti Aksnes
- Gloria Rashid
- Mona Elisabeth Revheim
- A. M. Mariathasan
Institutions
- Uppsala University (SE)
- Oslo University Hospital (NO)
- Uppsala University Hospital (SE)
- University of Oslo (NO)
- Oncoinvent (Norway) (NO)
Publication Details
- Journal
- Journal of Surgical Oncology
- Published
- 2024-10-20
- DOI
- https://doi.org/10.1002/jso.27897
- Citations
- 3
- Primary Topic
- Intraperitoneal and Appendiceal Malignancies
- Type
- article
- Field-Weighted Citation Impact
- 1.72